Avenue Therapeutics (49Y) Stock Statistics & Valuation Metrics
Total Valuation
Avenue Therapeutics has a market cap or net worth of EUR 1.26M. The enterprise value is -EUR 2.46M.
- Market Cap
- EUR 1.26M
- Enterprise Value
- -EUR 2.46M
Share Statistics
Avenue Therapeutics has 3,294,967 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,294,967
- Owned by Insiders
- ―
- Owned by Institutions
- 5.50%
Financial Efficiency
Avenue Therapeutics’s return on equity (ROE) is -1.59 and return on invested capital (ROIC) is -187.13%.
- Return on Equity (ROE)
- -1.59
- Return on Assets (ROA)
- -0.99
- Return on Invested Capital (ROIC)
- -187.13%
- Return on Capital Employed (ROCE)
- -1.79
- Revenue Per Employee
- 1.40M
- Profits Per Employee
- -2.91M
- Employee Count
- 1
- Asset Turnover
- 0.48
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Avenue Therapeutics is -0.50. Avenue Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.50
- PS Ratio
- 0.00
- PB Ratio
- 2.48
- Price to FCF
- -1.02
- Price to Operating Cash Flow
- -1.02
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Avenue Therapeutics had revenue of 1.40M and earned -2.91M in profits. Earnings per share was -0.93.
- Revenue
- 1.40M
- Gross Profit
- 1.40M
- Operating Income
- -3.29M
- Pretax Income
- -2.95M
- Net Income
- -2.91M
- EBITDA
- -3.29M
- Earnings Per Share (EPS)
- -0.93
Cash Flow
In the last 12 months, operating cash flow was -1.38M and capital expenditures 0, giving a free cash flow of -1.38M billion.
- Operating Cash Flow
- -1.38M
- Free Cash Flow
- -1.38M
- Free Cash Flow per Share
- -0.42
Dividends & Yields
Avenue Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -98.17%
- Earnings Yield
- -196.97%
Stock Price Statistics
- Beta
- -0.97
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.40
- 200-Day Moving Average
- 0.40
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Avenue Therapeutics upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Nov 17, 2025
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Avenue Therapeutics as a current ratio of 2.60, with Debt / Equity ratio of 0.00%
- Current Ratio
- 2.60
- Quick Ratio
- 2.60
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.87
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Avenue Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Avenue Therapeutics EV to EBITDA ratio is 0.17, with an EV/FCF ratio of 0.38.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.17
- EV to Free Cash Flow
- 0.38
- EV to Operating Cash Flow
- 0.38
Balance Sheet
Avenue Therapeutics has EUR 1.94M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 1.94M billion.
- Cash & Marketable Securities
- EUR 1.94M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 1.94M
- Net Cash Per Share
- EUR 0.59
- Tangible Book Value Per Share
- EUR 0.17
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
